CNS Pharmaceuticals, Inc. reported that on November 17, 2025, stockholders approved increasing authorized shares from 25M to 300M and made amendments to the 2020 Equity Plan, adding 114,916 shares. The event is significant for investors as it involves changes in capital structure and management decisions.